OVITRELLE is a recombinant human chorionic gonadotropin (r-hCG) indicated to treat women undergoing superovulation prior to assisted reproductive techniques, such as in vitrofertilisation (IVF). It is administered to trigger final follicular maturation and luteinisation after stimulation of follicular growth.1
The recombinant production process provides higher purity and consistent biopotency compared to the urinary hCG (u-hCG) production process.
OVITRELLE can give you the results you expect, with a dose of 250 µg r-hCG vs. u-hCG
OVITRELLE 250 μg (equivalent to 6,500 IU) is as effective as u-hCG 10,000 IU for final follicular maturation and luteinisation.